Loading clinical trials...
Loading clinical trials...
A Phase 1/2a First-In-Human, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CT3001 in Patients with Advanced Solid Tumors
Conditions
Interventions
CT3001
Locations
1
United States
MD Anderson Cancer Center
Houston, Texas, United States
Start Date
September 20, 2024
Primary Completion Date
June 20, 2027
Completion Date
June 30, 2027
Last Updated
November 4, 2024
NCT06144671
NCT07446322
NCT02600949
NCT05919264
NCT06921928
NCT06423326
Lead Sponsor
Crossignal Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions